Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: J Hepatol. 2019 Oct 10;72(1):146–155. doi: 10.1016/j.jhep.2019.09.030

Figure 6. VWF supplementation restores hepatic platelet accumulation and necrosis in APAP-challenged VWF−/− mice.

Figure 6.

APAP-challenged VWF−/− mice were supplemented with human plasma-derived VWF (3U VWF:RCo/mouse) or saline (i.e., control) 3h after APAP administration and samples were collected 48h after APAP challenge. Representative images showing immunolabeling of CD41 (platelets; red) and VWF (green) in DAPI (blue)-counterstained liver sections of saline-treated (A) and VWF-supplemented mice (B). Colocalization of VWF with platelets is indicated by yellow/orange. Original magnification is 100x. (C) Quantification of hepatic platelet accumulation in saline-treated (black bar) mice and VWF-supplemented (grey bar) mice, expressed as percentage of positive pixel count. (D) Representative photomicrographs of H&E-stained liver sections depict hepatocellular necrosis (closed triangle) and congestion/hemorrhage (asterisk). (E) Area of hepatocellular necrosis. Bars represent mean + standard error of the mean (n = 5-6 mice per group). * p<0.05 compared to saline-supplemented mice.